ArticleGenes & cancer2014

CDK4/6 inhibition provides a potent adjunct to Her2-targeted therapies in preclinical breast cancer models.

Agnieszka K Witkiewicz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.